Sept 8 (Reuters) - Catabasis Pharmaceuticals Inc :
* CATABASIS PHARMACEUTICALS ANNOUNCES NEW COMPANY NAME, ASTRIA THERAPEUTICS
* CATABASIS PHARMACEUTICALS INC - EXPECTS TO BEGIN TRADING UNDER NEW TICKER SYMBOL "ATXS" ON NASDAQ GLOBAL SELECT MARKET AT MARKET OPEN ON SEPTEMBER 9
* CATABASIS PHARMACEUTICALS INC - EXPECTS TO FILE IND APPLICATION FOR STAR-0215 IN MID-2022
* CATABASIS PHARMACEUTICALS - PLANS TO INITIATE PHASE 1 CLINICAL TRIAL WITH INITIAL PROOF OF CONCEPT RESULTS ANTICIPATED BY YEAR END 2022 FOR STAR-0125
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.